Enalaprilat injection is used in the management of hypertension when oral therapy is not practical.
Enalaprilat is the active metabolite of the oral prodrug enalapril maleate. Enalaprilat is poorly absorbed orally and must be administered intravenously. It inhibits angiotensin I to angiotensin II conversion via competitive inhibition of angiotensin-converting enzyme (ACE). This inhibition disrupts the renin-angiotensin-aldosterone system. Angiotensin II binds to AT1 receptors on smooth muscles to produce vasoconstriction and an increase in blood pressure. Additionally, angiotensin II stimulates the adrenal cortex to secrete aldosterone. Aldosterone causes the distal tubules and collecting ducts of the kidneys to reabsorb water and sodium in exchange for potassium, which results in an expansion in extracellular volume and an increase in blood pressure. Inhibition of ACE leads to decreased plasma angiotensin II, leading to vasodilation and decreased aldosterone secretion. Angiotensin II also causes vasoconstriction of the afferent and efferent arterioles of the kidney, exerting a more significant effect on the efferent arterioles. Enalaprilat administration in the presence of hypovolemia can cause renal injury due to inadequate renal perfusion. ACE breaks down bradykinin, a peptide that causes vasodilation. ACE inhibitors impede the breakdown of bradykinin, resulting in vasodilation and a bradykinin cough.
For Heart Failure:
For Renal Impairment:
Enalaprilat administration should be via IV push undiluted over at least 5 minutes or as an infusion diluted in up to 50 milliliters of D5W or 0.9% NaCl. Avoid salt substitutes or a potassium-rich diet. A dose no greater than 0.625 mg over 5 minutes should be administered in patients with heart failure or hyponatremia, and patients undergoing intensive diuresis, an increase in diuretic dose, or renal dialysis.
These adverse reactions may also be associated with enalapril because enalapril undergoes biotransformation to enalaprilat.
Warnings and Precautions
Enalaprilat is pregnancy Category C in the first trimester and Category D in the second and third trimesters. All ACE inhibitors can cause injury and even death to the fetus when used in pregnancy during the second and third trimesters. Hypotension, neonatal skull hypoplasia, anuria, and renal failure can also occur with use in pregnancy. If pregnancy is detected, discontinue enalaprilat should as soon as possible. Enalaprilat is also detectable in human breast milk, which creates a potential for adverse events in nursing infants. The safety and effectiveness of enalaprilat use in children have not been established. In elderly patients, dose selection should be modest and initiated at a low dose. Enalaprilat undergoes substantial excretion by the kidney, and the risk of toxic reactions may be higher in elderly patients with impaired renal function. With severe heart failure patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system, ACE inhibitor therapy may be associated with oliguria, progressive azotemia, acute renal failure, or death. In the absence of pre-existing renal vascular disease, it is still possible to develop increases in blood urea and serum creatinine. Hyperkalemia or elevated serum potassium greater than 5.7 mEq/L may occur in some hypertensive patients. Additional risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium supplements or potassium-sparing agents. In patients undergoing major surgery or anesthesia with agents that may cause hypotension, enalaprilat may block angiotensin II formation, and hypotension may result. This hypotension is correctable by volume expansion.
Monitoring parameters include blood pressure, BUN, serum creatinine, and potassium. Blood pressure needs close monitored with first dose administration or change in dose. If the patient has collagen vascular disease or renal impairment, complete blood count with differential is also a periodic monitoring requirement. Each patient should have an assessment for the presence of potential interactions with other medications that may impact their fluid balance or cardiac status. Monitoring for anaphylactic reactions, hypovolemia, angioedema, and postural hypotension is also necessary.
Cholestatic jaundice progressing to fulminant hepatic necrosis may occur. If a marked elevation of hepatic transaminases or jaundice occurs, then enalaprilat should be discontinued. Following the first dose or at any time during treatment, angioedema can occur. Angioedema of the face, extremities, lips, tongue, glottis, or larynx can lead to airway compromise. African Americans may be at an increased risk of developing angioedema. If angioedema occurs, immediately discontinue enalaprilat and initiate appropriate therapy with antihistamines and monitoring as necessary. When the tongue, glottis, or larynx is involved, subcutaneous epinephrine 1:1000 may be administered to reverse airway obstruction. A persistent, dry, hacking, nonproductive cough that occurs within the first few months of treatment can also occur with enalaprilat therapy. ACE inhibitor-induced cough is the result of the inhibition of the degradation of bradykinin and generally resolves within 1 to 4 weeks after discontinuation. Symptomatic hypotension, including syncope, can occur with ACE inhibitor therapy. Close monitoring and correction of volume depletion are necessary before initiating treatment. If hypotension occurs, consider reducing the enalaprilat dose, but do not abruptly discontinue therapy.
Enalaprilat is a widely used drug in the ICU for the management of hypertension. It is often prescribed by nurse practitioners, intensivists, cardiologists, and internists. The drug is effective with a rapid onset of action. However, nurses need to monitor the patient as hypotension can develop quickly. It is preferable to have an arterial line for continuous monitoring of the blood pressure while using enalaprilat.
|||Pongpanich P,Pitakpaiboonkul P,Takkavatakarn K,Praditpornsilpa K,Eiam-Ong S,Susantitaphong P, The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis. International urology and nephrology. 2018 Oct 15 [PubMed PMID: 30324578]|
|||Verbeeck RK,Kanfer I,Löbenberg R,Abrahamsson B,Cristofoletti R,Groot DW,Langguth P,Polli JE,Parr A,Shah VP,Mehta M,Dressman JB, Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Enalapril. Journal of pharmaceutical sciences. 2017 Aug [PubMed PMID: 28435140]|
|||Wolf S,Risler T, [Are all antihypertensive drugs renoprotective?]. Herz. 2004 May [PubMed PMID: 15167950]|
|||Sachs B,Meier T,Nöthen MM,Stieber C,Stingl J, [Drug-induced angioedema : Focus on bradykinin]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 2018 Apr [PubMed PMID: 29392343]|
|||Tabacova SA,Kimmel CA, Enalapril: pharmacokinetic/dynamic inferences for comparative developmental toxicity. A review. Reproductive toxicology (Elmsford, N.Y.). 2001 Sep-Oct [PubMed PMID: 11780954]|
|||Schubiger G,Flury G,Nussberger J, Enalapril for pregnancy-induced hypertension: acute renal failure in a neonate. Annals of internal medicine. 1988 Feb [PubMed PMID: 2829674]|
|||Cooper WO,Hernandez-Diaz S,Arbogast PG,Dudley JA,Dyer S,Gideon PS,Hall K,Ray WA, Major congenital malformations after first-trimester exposure to ACE inhibitors. The New England journal of medicine. 2006 Jun 8 [PubMed PMID: 16760444]|
|||"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Pediatrics. 1997 Feb [PubMed PMID: 9024461]|
|||Santoro A,Mandreoli M, [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)]. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia. 2018 May [PubMed PMID: 29786183]|
|||Walker SLM,Abbott TEF,Brown K,Pearse RM,Ackland GL, Perioperative management of angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers: a survey of perioperative medicine practitioners. PeerJ. 2018 [PubMed PMID: 30042876]|
|||Forner D,Kulai T,Arnason T,E Gruchy S,MacLeod M, Ramipril-associated cholestasis in the setting of recurrent drug-induced liver injury. Gastroenterology and hepatology from bed to bench. 2017 Spring [PubMed PMID: 28702139]|
|||Brown T,Gonzalez J,Monteleone C, Angiotensin-converting enzyme inhibitor-induced angioedema: A review of the literature. Journal of clinical hypertension (Greenwich, Conn.). 2017 Dec [PubMed PMID: 28994183]|